Merck Settles Patent Dispute over Keytruda with BMS, Ono for $625 Million plus Royalties

Merck has agreed to pay Bristol Myers Squibb and Ono Pharmaceutical $625 million, plus royalties on global Keytruda sales, to resolve patent-infringement allegations involving an antibody designed to treat cancer by reactivating the body’s anti-tumor immune response.
Source: Drug Industry Daily